Avidity Biosciences, Inc. (RNAM) Diversifiers

Equity · Currency in USD · Last updated Jun 5, 2026

Avidity Biosciences, Inc. develops RNA therapeutics called antibody oligonucleotide conjugates (AOCs) that combine monoclonal antibody specificity with RNA precision to target diseases previously untreatable with such therapeutics. The company's pipeline includes multiple clinical-stage programs for muscular dystrophies and precision cardiology candidates targeting rare genetic cardiomyopathies.

Looking to balance out your exposure to RNAM? The ETFs below have the lowest correlation with RNAM — they tend to move on their own, which can help reduce risk when RNAM drops. The stock ideas table highlights individual companies that behave independently from RNAM.

No Diversifiers Found for RNAM

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements RNAM

Add RNAM to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with RNAM